PSI 938

Drug Profile

PSI 938

Alternative Names: PSI-352938; PSI-938

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pharmasset
  • Class Antivirals; Purine nucleotides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 17 Jan 2012 Pharmasset has been acquired by Gilead Sciences
  • 01 Jan 2012 Pharmasset completes a phase I trial in Hepatitis C in USA and Puerto Rico (NCT01497327)
  • 21 Dec 2011 Pharmasset initiates enrolment in a phase I trial to PSI-938 and PSI-7977 in Hepatitis C positive patients with hepatic impairment in the US and Puerto Rico (NCT01497327).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top